In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Achieve Life Sciences (ACHV – Research Report), with a price target of $24.00. The company’s shares closed last Friday at $6.64.
According to TipRanks.com, Bernardino is a 5-star analyst with an average return of 21.1% and a 31.7% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Eledon Pharmaceuticals, Citius Pharmaceuticals, and Aridis Pharmaceuticals.
Achieve Life Sciences has an analyst consensus of Strong Buy, with a price target consensus of $26.67, representing a 315.2% upside. In a report issued on May 13, Maxim Group also initiated coverage with a Buy rating on the stock with a $21.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $10.40 and a one-year low of $5.62. Currently, Achieve Life Sciences has an average volume of 91.04K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products, cytisine, is a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
Read More on ACHV:
- H.C. Wainwright Thinks Eledon Pharmaceuticals’ Stock is Going to Recover
- H.C. Wainwright Sticks to Their Hold Rating for Iterum Therapeutics (ITRM)
- Akebia Therapeutics (AKBA) Gets a Hold Rating from H.C. Wainwright
- H.C. Wainwright Thinks Pulmatrix’s Stock is Going to Recover
- Micron (MU) Received its Third Buy in a Row
